EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population

Jeffrey S Berger, Veronica Ashton, François Laliberté, Guillaume Germain, Brahim Bookhart, Dominique Lejeune, Julien Boudreau, Patrick Lefebvre, Matthew R Weir

Advances in Therapy · 2023

DOI: 10.1007/s12325-022-02422-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2023. Verfasst von Jeffrey S Berger und 8 weiteren Autor:innen. Beteiligte Einrichtung: New York University School of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Diabetes Mellitus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Scientific Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The healthcare resource utilization (HRU) and costs of oral anticoagulant-naïve patients with non-valvular atrial fibrillation (NVAF) and diabetes initiated on rivaroxaban or warfarin in the United States (US) has not been previously evaluated. METHODS: This retrospective study used data from the Optum's de-identified Clinformatics® Data Mart Database (1 January, 2012 to 30 September, 2021) to evaluate the HRU and costs of adult patients with NVAF and diabetes newly initiated on rivaroxaban or warfarin (on or after January 2013). Inverse probability of treatment weighting (IPTW) was used to adjust for confounding between cohorts. HRU and costs (USD 2021) were assessed per patient-year (PPY) post-treatment initiation. Weighted cohorts were compared using rate ratios (RR) from Poisson regression models, odds ratios (OR) from logistic regression models, and cost differences; 95% confidence intervals (CI) and p values were generated using non-parametric bootstrap procedures. RESULTS: After IPTW, 17,881 and 19,274 patients initiated on rivaroxaban and warfarin were included, respectively (mean age: 73 years; 40% female). During 12 months of follow-up, the rivaroxaban cohort had lower all-cause HRU PPY across all components, including lower rates of inpatient stays (RR: 0.84, 95% CI 0.81, 0.88), outpatient visits (RR: 0.67, 95% CI 0.66, 0.68), and 30 day hospital readmission (OR: 0.75, 95% CI 0.66, 0.83; all p < 0.001) compared to the warfarin cohort. Moreover, rivaroxaban was associated with medical cost savings PPY (mean cost difference: - $9306, 95% CI - $11,769, - $6607), which compensated for higher pharmacy costs relative to warfarin (mean cost difference: $5518, 95% CI $5193, $5839), resulting in significantly lower all-cause total healthcare costs for rivaroxaban versus warfarin (mean cost difference: - $3788, 95% CI - $6258, - $1035; all p < 0.001). CONCLUSION: Among NVAF patients with diabetes in a real-world US setting, rivaroxaban was associated with lower healthcare costs compared to warfarin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeDiabetes MellitusAdultHumansFemaleUnited StatesAgedMaleWarfarinRivaroxabanRetrospective StudiesAnticoagulantsPatient Acceptance of Health CareDabigatran

Stichwörter der Autor:innen

DiabetesHealthcare costsHealthcare resource utilizationNon-valvular atrial fibrillationReal-worldRivaroxabanWarfarin

Substanzen

WarfarinRivaroxabanAnticoagulantsDabigatran

Autor:innen und Institutionen

  • New York University School of Medicine, New York, NY, USA.
  • Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
  • Groupe d'analyse, Ltée, 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montreal, QC, H3B 0G7, Canada.
  • Groupe d'analyse, Ltée, 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montreal, QC, H3B 0G7, Canada. guillaume.germain@analysisgroup.com.
  • University of Maryland School of Medicine, Baltimore, MD, USA.

Förderung

  • Janssen Scientific Affairs

Zitieren

APA

Berger, J. S., Ashton, V., Laliberté, F., Germain, G., Bookhart, B., Lejeune, D., Boudreau, J., Lefebvre, P., & Weir, M. R. (2023). Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population. Advances in Therapy. https://doi.org/10.1007/s12325-022-02422-9

Vancouver

Berger JS, Ashton V, Laliberté F, Germain G, Bookhart B, Lejeune D, et al. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population. Advances in Therapy. 2023. doi:10.1007/s12325-022-02422-9

BibTeX
@article{Berger2023,
  author = {Berger, Jeffrey S and Ashton, Veronica and Laliberté, François and Germain, Guillaume and Bookhart, Brahim and Lejeune, Dominique and Boudreau, Julien and Lefebvre, Patrick and Weir, Matthew R},
  title = {Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population},
  journal = {Advances in Therapy},
  year = {2023},
  doi = {10.1007/s12325-022-02422-9}
}
Kostenlos starten →